Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Non-squamous Non-small Cell Lung Cancer × camrelizumab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 3 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Pancreatic Neoplasms 1 Non-squamous Non-small Cell Lung Cancer 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Liver Neoplasms 1 Hodgkin Disease 1 Hepatoblastoma 1 Breast Neoplasms 1 Advanced Solid Tumor 1 Adenocarcinoma 1

Interventions

camrelizumab 1 Pemetrexed 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06335355 2024-03-28

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Shanghai Shengdi Pharmaceutical Co., Ltd

Phase 2/3 Not yet recruiting

Non-squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡